Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1553-1556

  Dogan, Mutlu ^a   Karabulut, Halil G ^a   Tukun, Ajlan ^a   Demirkazik, Ahmet ^a   Utkan, Gungor ^a   Yalcin, Bulent ^a   Dincol, Dilek ^a   Akbulut, Hakan ^a   Icli, Fikri ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Antimetabolite toxicity; Fluorouracil; Methotrexate; Pharmacogenetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; DNA BINDING PROTEIN; DRUG DERIVATIVE; FLUOROURACIL; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; THYMIDYLATE SYNTHASE; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; FEMALE; GASTROINTESTINAL TUMOR; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; OSTEOSARCOMA; TURKEY (REPUBLIC); VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DNA; DNA-BINDING PROTEINS; DRUG ERUPTIONS; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GENE FREQUENCY; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MINISATELLITE REPEATS; MUCOSITIS; OSTEOSARCOMA; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE; TURKEY; XERODERMA PIGMENTOSUM GROUP D PROTEIN; YOUNG ADULT;

EID: 84873051305     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1553     Document Type: Article

References (15)

1. Campalani E, Arenas M, Marinaki M, et al (2007). Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol, 127, 1860-7.
2. Dervieux T, Meshkin B, Neri B (2005). Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res, 573, 180-94.
3. Goyette P, Pai A, Milos R, et al (1998). Gene structure of human and mouse methylenetetrahydrofolate reductase. Mamm Genome, 9, 652-6.
4. Gross E, Busse B, Riemenschneider M, et al (2008). Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One, 3, e4003, 1-7.
5. Kantar M, Kosova B, Cetingul N, et al (2009). Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma, 50, 912-7.
6. López-Cima MF, González-Arriaga P, García-Castro L, et al (2007). Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population ofnorthern Spain. BMC Cancer, 7, 162-73.
7. Magné N, Etienne-Grimaldi MC, Cals L, et al (2007). Dihydropryrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J lin Pharmacol, 64, 237-40.
8. Meta-Analysis Group in Cancer (1998). Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol, 16, 3537-41.
9. Sliwinski T, Krupa R, Wisniewska-Jarosinska M et al (2009). Common polymorphisms in the XPD and hOGG1 genes are not associated with the risk of colorectal cancer in a Polish population. Tohoku J Exp Med, 218, 185-91.
10. Sreeja L, Syamala VS, Syamala V, et al (2008). Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol, 134, 645-52.
11. Toffoli G, de Mattia E (2008). Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics, 9, 1195-206.
12. Van Kuilenburg AB, Haasjes J, Richel DJ, et al (2000). Clinical Implications of Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Patients with Severe 5-Fluorouracil-associated Toxicity: Identification of New Mutations in the DPD Gene Clinical Cancer Research, 6, 4705-12.
13. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002). Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydroprymidine dehydrogenase deficiency: high prevelance of the IVS14-1G-A mutation. Int J Cancer, 101, 253-8.
14. Van Kuilenburg AB (2004). Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer, 40, 939-50.
15. Wang M, Gu D, Zhang Z, et al (2009). XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A, 72, 698-05.